PLG 抗体 (AA 251-350) (Biotin)
Quick Overview for PLG 抗体 (AA 251-350) (Biotin) (ABIN735040)
抗原
See all PLG 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 251-350
-
交叉反应
- 人
-
预测反应
- Mouse,Rat,Dog,Cow,Pig
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from human PLG
-
亚型
- IgG
-
-
-
-
应用备注
-
WB 1:300-5000
IHC-P 1:200-400 -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- Store at -20°C for 12 months.
-
有效期
- 12 months
-
-
- PLG (Plasminogen (PLG))
-
别名
- Plasminogen
-
背景
-
Synonyms: Plasminogen, Angiostatin, DKFZp779M0222, Microplasmin, Plasmin, Plasmin heavy chain A, PLG, PLMN_HUMAN.
Background: Plasminogen is a plasma protein synthesised mostly in the liver. Plasma concentration is usually in the range of 70 to 200 mg/l. Plasminogen is activated by tissue plasminogen activator, urokinase and streptokinase, to form plasmin. Activation results from the cleavage and release of the preactivation peptide. Angiostatin, an internal fragment of plasminogen, is a potent inhibitor of angiogenesis, which selectively inhibits endothelial cell proliferation. Angiostatin potently inhibits tumor growth and can maintain metastatic and primary tumors in a dormant state. It is defined by a balance of proliferation and apoptosis of the tumor cells and is composed of plasminogen first four cringle structures. This molecule is generated by proteolytic cleavage of plasminogen.
-
基因ID
- 5340
-
UniProt
- P00747
-
途径
- Complement System, Lipid Metabolism
抗原
-